Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells

Seminars in Immunology

Volumn 28, Issue 2, 2016, Pages 187-196

  Moses, Katrin ^a   Brandau, Sven ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cancer progression; Immunosuppression; Low density neutrophils; Myeloid derived suppressor cells; Polymorphonuclear neutrophil granulocytes; Tumor associated neutrophils

Indexed keywords

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CIRCULATING TUMOR CELL; HUMAN; LOW DENSITY NEUTROPHIL; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL; NEUTROPHIL LYMPHOCYTE RATIO; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; DISEASE EXACERBATION; DISEASE PREDISPOSITION; IMMUNOLOGY; IMMUNOMODULATION; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PROGNOSIS; TUMOR MICROENVIRONMENT;

BIOLOGICAL MARKER;

ANIMALS; BIOMARKERS; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNOMODULATION; LEUKOCYTE COUNT; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; NEUTROPHIL ACTIVATION; NEUTROPHIL INFILTRATION; NEUTROPHILS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84962762345     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.03.018     Document Type: Review

References (126)

1. Dumitru C.A., Lang S., Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin. Cancer Biol. 2013, 23:141-148.
2. Liang W., Ferrara N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol. Res. 2016, 4:83-91.
3. Gentles A.J., Newman A.M., Liu C.L., Bratman S.V., Feng W., Kim D., Nair V.S., Xu Y., Khuong A., Hoang C.D., Diehn M., West R.B., Plevritis S.K., Alizadeh A.A. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 2015, 21:938-945.
4. Shen M., Hu P., Donskov F., Wang G., Liu Q., Du J. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One 2014, 9. e98259.
5. Shoenfeld Y., Tal A., Berliner S., Pinkhas J. Leukocytosis in non hematological malignancies-a possible tumor-associated marker. J. Cancer Res. Clin. Oncol. 1986, 111:54-58.
6. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin. Cancer Biol. 2013, 23:200-207.
7. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., Ugel S., Sonda N., Bicciato S., Falisi E., Calabrese F., Basso G., Zanovello P., Cozzi E., Mandruzzato S., Bronte V. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010, 32:790-802.
8. Trellakis S., Bruderek K., Hütte J., Elian M., Hoffmann T.K., Lang S., Brandau S. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun. 2013, 19:328-336.
9. Annels N.E., Shaw V.E., Gabitass R.F., Billingham L., Corrie P., Eatock M., Valle J., Smith D., Wadsley J., Cunningham D., Pandha H., Neoptolemos J.P., Middleton G. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol. Immunother. 2014, 63:175-183.
10. Brandau S., Moses K., Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins siblings or twins?. Semin. Cancer Biol. 2013, 23:171-182.
11. Pillay J., Tak T., Kamp V.M., Koenderman L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell. Mol. Life Sci. 2013, 70:3813-3827.
12. Fridlender Z., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G., Albelda S. Polarization of tumor-associated neutrophil phenotype by TGF-beta: n1 versus N2 TAN. Cancer Cell 2009, 16:183-194.
13. Andzinski L., Kasnitz N., Stahnke S., Wu C.-F., Gereke M., von Köckritz-Blickwede M., Schilling B., Brandau S., Weiss S., Jablonska J. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer 2016, 138:1982-1993.
14. Kuang D., Zhao Q., Wu Y., Peng C., Wang J., Xu Z., Yin X., Zheng L. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J. Hepatol. 2011, 54:948-955.
15. Trellakis S., Bruderek K., Dumitru C., Gholaman H., Gu X., Bankfalvi A., Scherag A., Hutte J., Dominas N., Lehnerdt G., Hoffmann T., Lang S., Brandau S. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int. J. Cancer 2011, 129:2183-2193.
16. Shamamian P., Schwartz J., Pocock B., Monea S., Whiting D., Marcus S., Mignatti P. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J. Cell Physiol. 2001, 189:197-206.
17. Wang J., Jia Y., Wang N., Zhang X., Tan B., Zhang G., Cheng Y. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J. Transl. Med. 2014, 12:7.
18. Uribe-Querol E., Rosales C. Neutrophils in cancer: two sides of the same coin. J. Immunol. Res. 2015, 2015:983698.
19. Tecchio C., Scapini P., Pizzolo G., Cassatella M.A. On the cytokines produced by human neutrophils in tumors. Semin. Cancer Biol. 2013, 23:159-170.
20. Jurcevic S., Humfrey C., Uddin M., Warrington S., Larsson B., Keen C. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br. J. Clin. Pharmacol. 2015, 80:1324-1336.
21. Porembka M.R., Mitchem J.B., Belt B.A., Hsieh C.-S., Lee H.-M., Herndon J., Gillanders W.E., Linehan D.C., Goedegebuure P. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol. Immunother. 2012, 61:1373-1385.
22. Hagerling C., Werb Z. Neutrophils: Critical components in experimental animal models of cancer. Semin. Immunol. 2016, 28:197-204.
23. Jensen T.O., Schmidt H., Møller H.J., Donskov F., Høyer M., Sjoegren P., Christensen I.J., Steiniche T. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012, 118:2476-2485.
24. Grégoire M., Guilloton F., Pangault C., Mourcin F., Sok P., Latour M., Amé-Thomas P., Flecher E., Fest T., Tarte K. Neutrophils trigger a NF-(B dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. Oncotarget 2015, 6:16471-16487.
25. Li L., Xu L., Yan J., Zhen Z.-J., Ji Y., Liu C.-Q., Lau W.Y., Zheng L., Xu J. CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2015, 34:129.
26. Schwaller J., Schneider P., Mhawech-Fauceglia P., McKee T., Myit S., Matthes T., Tschopp J., Donze O., Le Gal F., Huard B. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 2007, 109:331-338.
27. Eruslanov E.B., Bhojnagarwala P.S., Quatromoni J.G., Stephen T.L., Ranganathan A., Deshpande C., Akimova T., Vachani A., Litzky L., Hancock W.W., Conejo-Garcia J.R., Feldman M., Albelda S.M., Singhal S. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Invest. 2014, 124:5466-5480.
28. He G., Zhang H., Zhou J., Wang B., Chen Y., Kong Y., Xie X., Wang X., Fei R., Wei L., Chen H., Zeng H. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2015, 34:141.
29. Wu P., Wu D., Ni C., Ye J., Chen W., Hu G., Wang Z., Wang C., Zhang Z., Xia W., Chen Z., Wang K., Zhang T., Xu J., Han Y., Zhang T., Wu X., Wang J., Gong W., Zheng S., Qiu F., Yan J., Huang J. T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014, 40:785-800.
30. Reid M.D., Basturk O., Thirabanjasak D., Hruban R.H., Klimstra D.S., Bagci P., Altinel D., Adsay V. Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod. Pathol. 2011, 24:1612-1619.
31. Sadot E., Basturk O., Klimstra D.S., Gönen M., Lokshin A., Do R.K.G., D'Angelica M.I., DeMatteo R.P., Kingham T.P., Jarnagin W.R., Allen P.J. Tumor-associated neutrophils and malignant progression in intraductal papillary mucinous neoplasms: an opportunity for identification of high-risk disease. Ann. Surg. 2015, 262:1102-1107.
32. Berger-Achituv S., Brinkmann V., Abed U.A., Kühn L.I., Ben-Ezra J., Elhasid R., Zychlinsky A. A proposed role for neutrophil extracellular traps in cancer immunoediting. Front. Immunol. 2013, 4:48.
33. Rotondo R., Barisione G., Mastracci L., Grossi F., Orengo A., Costa R., Truini M., Fabbi M., Ferrini S., Barbieri O. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int. J. Cancer 2009, 125:887-893.
34. Kadota K., Nitadori J.-i., Ujiie H., Buitrago D.H., Woo K.M., Sima C.S., Travis W.D., Jones D.R., Adusumilli P.S. Prognostic impact of immune microenvironment in lung squamous cell carcinoma: tumor-infiltrating CD10+ Neutrophil/CD20+ lymphocyte ratio as an independent prognostic factor. J. Thorac. Oncol. 2015, 10:1301-1310.
35. Ibrahim S.A., Katara G.K., Kulshrestha A., Jaiswal M.K., Amin M.A., Beaman K.D. Breast cancer associated a2 isoform vacuolar ATPase immunomodulates neutrophils: potential role in tumor progression. Oncotarget 2015, 6:33033-33045.
36. Fossati G., Ricevuti G., Edwards S., Walker C., Dalton A., Rossi M. Neutrophil infiltration into human gliomas. Acta Neuropathol. 1999, 98:349-354.
37. Droeser R.A., Hirt C., Eppenberger-Castori S., Zlobec I., Viehl C.T., Frey D.M., Nebiker C.A., Rosso R., Zuber M., Amicarella F., Iezzi G., Sconocchia G., Heberer M., Lugli A., Tornillo L., Oertli D., Terracciano L., Spagnoli G.C. High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One 2013, 8:e64814.
38. Raychaudhuri B., Rayman P., Huang P., Grabowski M., Hambardzumyan D., Finke J.H., Vogelbaum M.A. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J. Neurooncol. 2015, 122:293-301.
39. Guislain A., Gadiot J., Kaiser A., Jordanova E.S., Broeks A., Sanders J., van Boven H., de Gruijl T.D., Haanen J.B.A.G., Bex A., Blank C.U. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol. Immunother. 2015, 64:1241-1250.
40. Bronte V., Brandau S., Chen S.-H., Colombo M.P., Frey A.B., Greten T.F., Mandruzzato S., Murray P.J., Ochoa A., Ostrand-Rosenberg S., Rodriguez P.C., Sica A., Umansky V., Vonderheide R.H., Gabrilovich D.I. Myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 2016, (Ms in revision).
41. Wislez M., Rabbe N., Marchal J., Milleron B., Crestani B., Mayaud C., Antoine M., Soler P., Cadranel J. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res. 2003, 63:1405-1412.
42. Punt S., Fleuren G.J., Kritikou E., Lubberts E., Trimbos J.B., Jordanova E.S., Gorter A. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology 2015, 4. e984539.
43. Dumitru C., Fechner M., Hoffmann T., Lang S., Brandau S. A novel p38-MAPK signaling axis modulates neutrophil biology in head and neck cancer. J. Leukoc. Biol. 2012, 91:591-598.
44. Hu P., Shen M., Zhang P., Zheng C., Pang Z., Zhu L., Du J. Intratumoral neutrophil granulocytes contribute to epithelial-mesenchymal transition in lung adenocarcinoma cells. Tumour Biol. 2015, 36:7789-7796.
45. Grosse-Steffen T., Giese T., Giese N., Longerich T., Schirmacher P., Hänsch G.M., Gaida M.M. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase. Clin. Dev. Immunol. 2012, 2012. 720768.
46. Mishalian I., Bayuh R., Eruslanov E., Michaeli J., Levy L., Zolotarov L., Singhal S., Albelda S., Granot Z., Fridlender Z. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17-a new mechanism of impaired antitumor immunity. Int. J. Cancer 2014, 135:1178-1186.
47. Zhu Q., Zhang X., Zhang L., Li W., Wu H., Yuan X., Mao F., Wang M., Zhu W., Qian H., Xu W. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis. 2014, 5:e1295.
48. Mishalian I., Bayuh R., Levy L., Zolotarov L., Michaeli J., Fridlender Z. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol. Immunother. 2013, 62:1745-1756.
49. Souto J.C., Vila L., Brú A. Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med. Res. Rev. 2011, 31:311-363.
50. Cho H., Hur H., Kim S., Kim S., Kim J., Kim Y., Lee K. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol. Immunother. 2009, 58:15-23.
51. Arigami T., Okumura H., Matsumoto M., Uchikado Y., Uenosono Y., Kita Y., Owaki T., Mori S., Kurahara H., Kijima Y., Ishigami S., Natsugoe S. Analysis of the fibrinogen and neutrophil-lymphocyte ratio in esophageal squamous cell carcinoma: a promising blood marker of tumor progression and prognosis. Medicine 2015, 94:e1702.
52. Trellakis S., Farjah H., Bruderek K., Dumitru C., Hoffmann T., Lang S., Brandau S. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int. J. Immunopathol. Pharmacol. 2011, 24:683-693.
53. Tanaka F., Goto H., Yokosuka T., Yanagimachi M., Kajiwara R., Naruto T., Nishimaki S., Yokota S. Suppressed neutrophil function in children with acute lymphoblastic leukemia. Int. J. Hematol. 2009, 90:311-317.
54. Uehara M., Sato N. Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma. Hepatology 1994, 20:326-330.
55. Tsuda Y., Fukui H., Asai A., Fukunishi S., Miyaji K., Fujiwara S., Teramura K., Fukuda A., Higuchi K. An immunosuppressive subtype of neutrophils identified in patients with hepatocellular carcinoma. J. Clin. Biochem. Nutr. 2012, 51:204-212.
56. Bednarska K., Klink M., Wilczynski J.R., Szyo K., Malinowski A., Suowska Z., Nowak M. Heterogeneity of the Mac-1 expression on peripheral blood neutrophils in patients with different types of epithelial ovarian cancer. Immunobiology 2016, 221:323-332.
57. Choi J., Suh B., Ahn Y., Kim T., Lee J., Lee S., Heo D. CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumour Biol. 2012, 33:121-129.
58. Ma J., Li N., Lin Y., Gupta C., Jiang F. Circulating neutrophil MicroRNAs as biomarkers for the detection of lung cancer. Biomark. Cancer 2016, 8:1-7.
59. Yang C., Sun W., Cui W., Li X., Yao J., Jia X., Li C., Wu H., Hu Z., Zou X. Procoagulant role of neutrophil extracellular traps in patients with gastric cancer. Int J Clin Exp Pathol 2015, 8:14075-14086.
60. Thålin C., Demers M., Blomgren B., Wong S.L., von Arbin M., von Heijne A., Laska A.C., Wallén H., Wagner D.D., Aspberg S. NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb. Res. 2016, 139:56-64.
61. Tohme S., Yazdani H.O., Al-Khafaji A.B., Chidi A.P., Lougharn P., Mowen K., Wang Y., Simmons R.L., Huang H., Tsung A. Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Cancer Res. 2016, (Epub ahead of print). 10.1158/0008-5472.CAN-15-1591.
62. Takakura K., Ito Z., Suka M., Kanai T., Matsumoto Y., Odahara S., Matsudaira H., Haruki K., Fujiwara Y., Saito R., Gocho T., Nakashiro K.-I., Hamakawa H., Okamoto M., Kajihara M., Misawa T., Ohkusa T., Koido S. Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour site. Scand. J. Gastroenterol. 2016, 51:610-617.
63. Fridlender Z., Sun J., Mishalian I., Singhal S., Cheng G., Kapoor V., Horng W., Fridlender G., Bayuh R., Worthen G., Albelda S. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One 2012, 7:e31524.
64. Jablonska E., Puzewska W., Grabowska Z., Jablonski J., Talarek L. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine 2005, 30:93-99.
65. Maenhout S.K., Thielemans K., Aerts J.L. Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells. Oncoimmunology 2014, 3:e956579.
66. Sagiv J.Y., Michaeli J., Assi S., Mishalian I., Kisos H., Levy L., Damti P., Lumbroso D., Polyansky L., Sionov R.V., Ariel A., Hovav A.-H., Henke E., Fridlender Z.G., Granot Z. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015, 10:562-573.
67. Schmielau J., Finn O. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001, 61:4756-4760.
68. Brandau S., Trellakis S., Bruderek K., Schmaltz D., Steller G., Elian M., Suttmann H., Schenck M., Welling J., Zabel P., Lang S. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 2011, 89:311-317.
69. Rodriguez P., Ernstoff M., Hernandez C., Atkins M., Zabaleta J., Sierra R., Ochoa A. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69:1553-1560.
70. Fujimoto H., Sakata T., Hamaguchi Y., Shiga S., Tohyama K., Ichiyama S., Wang F., Houwen B. Flow cytometric method for enumeration and classification of reactive immature granulocyte populations. Cytometry 2000, 42:371-378.
71. Elghetany M. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol. Dis. 2002, 28:260-274.
72. Hu H., Shikama Y., Shichishima T., Ikeda K., Akutsu K., Ono T., Kimura H., Ogawa K., Noji H., Takeishi Y., Kimura J. Maturity-dependent fractionation of neutrophil progenitors: a new method to examine in vivo expression profiles of differentiation-regulating genes. Exp. Hematol. 2012, 40:675-681.
73. Fu B.-H., Fu Z.-Z., Meng W., Gu T., Sun X.-D., Zhang Z. Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients. Tumour Biol. 2015, 36:6477-6483.
74. Tas F., Karabulut S., Yasasever C.T., Duranyildiz D. Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma. Tumour Biol. 2014, 35:7233-7237.
75. Chiorean R., Berindan-Neagoe I., Braicu C., Florian I.S., Leucuta D., Crisan D., Cernea V. Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: correlations with clinical data. Cancer Biomark. 2014, 14:185-194.
76. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6742-6747.
77. Bendall L.J., Bradstock K.F. G-CSF from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014, 25:355-367.
78. Raychaudhuri B., Rayman P., Ireland J., Ko J., Rini B., Borden E., Garcia J., Vogelbaum M., Finke J. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro. Oncol. 2011, 13:591-599.
79. Köhler A., De Filippo K., Hasenberg M., van den Brandt C., Nye E., Hosking M.P., Lane T.E., Männ L., Ransohoff R.M., Hauser A.E., Winter O., Schraven B., Geiger H., Hogg N., Gunzer M. G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood 2011, 117:4349-4357.
80. Gabitass R., Annels N., Stocken D., Pandha H., Middleton G. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 2011, 60:1419-1430.
81. Youn J., Nagaraj S., Collazo M., Gabrilovich D. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
82. Dumitru C., Moses K., Trellakis S., Lang S., Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother. 2012, 61:1155-1167.
83. Solito S., Marigo I., Pinton L., Damuzzo V., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N. Y. Acad. Sci. 2014, 1319:47-65.
84. Mishalian I., Granot Z., Fridlender Z.G. The diversity of circulating neutrophils in cancer. Immunobiology 2016, (Epub ahead of print). 10.1016/j.imbio.2016.02.001.
85. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P., Chudnovskiy A., Berger C., Ryan R., Iwamoto Y., Marinelli B., Gorbatov R., Forghani R., Novobrantseva T., Koteliansky V., Figueiredo J., Chen J., Anderson D., Nahrendorf M., Swirski F., Weissleder R., Pittet M. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2491-2496.
86. Ribechini E., Greifenberg V., Sandwick S., Lutz M. Subsets, expansion and activation of myeloid-derived suppressor cells. Med. Microbiol. Immunol. 2010, 199:273-281.
87. Damuzzo V., Pinton L., Desantis G., Solito S., Marigo I., Bronte V., Mandruzzato S. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin. Cytom. 2015, 88:77-91.
88. Scapini P., Cassatella M.A. Social networking of human neutrophils within the immune system. Blood 2014, 124:710-719.
89. Piccard H., Muschel R.J., Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit. Rev. Oncol. Hematol. 2012, 82:296-309.
90. Mandruzzato S., Brandau S., Britten C.M., Bronte V., Damuzzo V., Gouttefangeas C., Maurer D., Ottensmeier C., van der Burg S.H., Welters M.J.P., Walter S. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol. Immunother. 2016, 65:161-169.
91. Mye-Euniter webpage,. http://www.mye-euniter.eu.
92. Zhang G.-M., Zhu Y., Ma X.-C., Qin X.-J., Wan F.-N., Dai B., Sun L.-J., Ye D.-W. Pretreatment neutrophil-to-lymphocyte ratio: a predictor of advanced prostate cancer and biochemical recurrence in patients receiving radical prostatectomy. Medicine 2015, 94:e1473.
93. van Soest R.J., Templeton A.J., Vera-Badillo F.E., Mercier F., Sonpavde G., Amir E., Tombal B., Rosenthal M., Eisenberger M.A., Tannock I.F., de Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann. Oncol. 2015, 26:743-749.
94. Lorente D., Mateo J., Templeton A.J., Zafeiriou Z., Bianchini D., Ferraldeschi R., Bahl A., Shen L., Su Z., Sartor O., de Bono J.S. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann. Oncol. 2015, 26:750-755.
95. Gu X., Gao X., Li X., Qi X., Ma M., Qin S., Yu H., Sun S., Zhou D., Wang W. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci. Rep. 2016, 6:22089.
96. Goldstein D., El-Maraghi R.H., Hammel P., Heinemann V., Kunzmann V., Sastre J., Scheithauer W., Siena S., Tabernero J., Teixeira L., Tortora G., Van Laethem J.-L., Young R., Penenberg D.N., Lu B., Romano A., Von Hoff D.D. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J. Natl. Cancer Inst. 2015, 107:dju413.
97. Hsu J.-T., Liao C.-K., Le P.-H., Chen T.-H., Lin C.-J., Chen J.-S., Chiang K.-C., Yeh T.-S. Prognostic value of the preoperative neutrophil to lymphocyte ratio in resectable gastric cancer. Medicine 2015, 94:e1589.
98. Bazzi W.M., Tin A.L., Sjoberg D.D., Bernstein M., Russo P. The prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinoma. Can. J. Urol. 2016, 23:8151-8154.
99. Pistelli M., De Lisa M., Ballatore Z., Caramanti M., Pagliacci A., Battelli N., Ridolfi F., Santoni M., Maccaroni E., Bracci R., Santinelli A., Biscotti T., Berardi R., Cascinu S. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer 2015, 15:195.
100. Ulas A., Avci N., Kos T., Cubukcu E., Olmez O.F., Bulut N., Degirmenci M. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?. J. BUON 2015, 20:714-722.
101. Diaz-Montero C., Salem M., Nishimura M., Garrett-Mayer E., Cole D., Montero A. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49-59.
102. Mundy-Bosse B., Young G., Bauer T., Binkley E., Bloomston M., Bill M., Bekaii-Saab T., Carson I., Lesinski W.E.G. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4 T cells from patients with GI malignancy. Cancer Immunol. Immunother. 2011, 60:1269-1279.
103. Liu C., Wang Y., Wang C., Feng P., Ko H., Liu Y., Wu Y., Chu Y., Chung F., Kuo C., Lee K., Lin S., Lin H., Wang C., Yu C., Kuo H. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2010, 136:35-45.
104. Angell T.E., Lechner M.G., Smith A.M., Martin S.E., Groshen S.G., Maceri D.R., Singer P.A., Epstein A.L. Circulating myeloid-derived suppressor cells predict differentiated thyroid cancer diagnosis and extent. Thyroid 2016, (Epub ahead of print). 10.1089/thy.2015.0289.
105. Kawano M., Mabuchi S., Matsumoto Y., Sasano T., Takahashi R., Kuroda H., Kozasa K., Hashimoto K., Isobe A., Sawada K., Hamasaki T., Morii E., Kimura T. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci. Rep. 2015, 5:18217.
106. Mayanagi S., Kitago M., Sakurai T., Matsuda T., Fujita T., Higuchi H., Taguchi J., Takeuchi H., Itano O., Aiura K., Hamamoto Y., Takaishi H., Okamoto M., Sunamura M., Kawakami Y., Kitagawa Y. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci. 2015, 106:397-406.
107. Schneider T., Sevko A., Heussel C.P., Umansky L., Beckhove P., Dienemann H., Safi S., Utikal J., Hoffmann H., Umansky V. Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clin. Exp. Immunol. 2015, 180:467-474.
108. Li J., Srivastava R.M., Ettyreddy A., Ferris R.L. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J. Immunother. Cancer 2015, 3:54.
109. Ilie M., Hofman V., Ortholan C., Bonnetaud C., Coelle C., Mouroux J., Hofman P. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil- to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 2011, 118:1726-1737.
110. Donskov F., von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:1997-2005.
111. Caruso R.A., Bellocco R., Pagano M., Bertoli G., Rigoli L., Inferrera C. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod. Pathol. 2002, 15:831-837.
112. Galdiero M.R., Bianchi P., Grizzi F., Di Caro G., Basso G., Ponzetta A., Bonavita E., Barbagallo M., Tartari S., Polentarutti N., Malesci A., Marone G., Roncalli M., Laghi L., Garlanda C., Mantovani A., Jaillon S. Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer. Int. J. Cancer 2016, Epub ahead of print. 10.1002/ijc.30076.
113. Fernández A., Oliver L., Alvarez R., Fernández L.E., Lee K.P., Mesa C. Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum. Vaccine Immunother. 2014, 10:3251-3260.
114. Arina A., Bronte V. Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Curr. Opin. Immunol. 2015, 33:120-125.
115. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100:228-237.
116. Di Maio M., Gridelli C., Gallo C., Shepherd F., Piantedosi F.V., Cigolari S., Manzione L., Illiano A., Barbera S., Robbiati S.F., Frontini L., Piazza E., Ianniello G.P., Veltri E., Castiglione F., Rosetti F., Gebbia V., Seymour L., Chiodini P., Perrone F. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005, 6:669-677.
117. Highfill S., Cui Y., Giles A., Smith J., Zhang H., Morse E., Kaplan R., Mackall C. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-pD1 efficacy. Sci. Transl. Med. 2014, 6(237). ra67.
118. Rennard S.I., Dale D.C., Donohue J.F., Kanniess F., Magnussen H., Sutherland E.R., Watz H., Lu S., Stryszak P., Rosenberg E., Staudinger H. CXCR2 antagonist MK-7123. a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015, 191:1001-1011.
119. Pico de Coaña Y., Poschke I., Gentilcore G., Mao Y., Nyström M., Hansson J., Masucci G.V., Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol. Res. 2013, 1:158-162.
120. Califano J.A., Khan Z., Noonan K.A., Rudraraju L., Zhang Z., Wang H., Goodman S., Gourin C.G., Ha P.K., Fakhry C., Saunders J., Levine M., Tang M., Neuner G., Richmon J.D., Blanco R., Agrawal N., Koch W.M., Marur S., Weed D.T., Serafini P., Borrello I. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2015, 21:30-38.
121. Benevides L., da Fonseca D.M., Donate P.B., Tiezzi D.G., De Carvalho D.D., de Andrade J.M., Martins G.A., Silva J.S. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Res. 2015, 75:3788-3799.
122. Cohen C.A., Shea A.A., Heffron C.L., Schmelz E.M., Roberts P.C. Interleukin-12 immunomodulation delays the onset of lethal peritoneal disease of ovarian cancer. J. Interferon Cytokine Res. 2016, 36:62-73.
123. Sanford D.E., Porembka M.R., Panni R.Z., Mitchem J.B., Belt B.A., Plambeck-Suess S.M., Lin G., Denardo D.G., Fields R.C., Hawkins W.G., Strasberg S.M., Lockhart A.C., Wang-Gillam A., Goedegebuure S.P., Linehan D.C. A study of zoledronic acid as neo-adjuvant, perioperative therapy in patients with resectable pancreatic ductal adenocarcinoma. J. Cancer Ther. 2013, 4:797-803.
124. Cohn A., Lahn M.M., Williams K.E., Cleverly A.L., Pitou C., Kadam S.K., Farmen M.W., Desaiah D., Raju R., Conkling P., Richards D. A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer. Int. J. Oncol. 2014, 45:2221-2231.
125. Rodon J., Carducci M.A., Sepulveda-Sánchez J.M., Azaro A., Calvo E., Seoane J., Braña I., Sicart E., Gueorguieva I., Cleverly A.L., Pillay N.S., Desaiah D., Estrem S.T., Paz-Ares L., Holdhoff M., Blakeley J., Lahn M.M., Baselga J. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin. Cancer Res. 2015, 21:553-560.
126. Brandau S., Dumitru C., Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin. Immunopathol. 2013, 35:163-176.